Cat.No. | Name | Information |
---|---|---|
M1806 | PD 0332991 HCL | PD-0332991 HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. |
M1974 | Roscovitine (Seliciclib) | Roscovitine is a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. |
M2112 | LY2835219 mesylate | LY2835219 mesylate is an orally available inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM, respectively. |
M1807 | SCH727965 (dinaciclib) | SCH727965 (Dinaciclib) is a potent and selective CDK inhibitor with IC50 values of 1, 1, 3 and 4 nM for CDK2, CDK5, CDK1 and CDK9, respectively. |
M3519 | PHA-848125 | PHA-848125 is a potent, ATP-competitive CDK inhibitor for CDK2 with IC50 of 45 nM. It is >3-fold more selective for CDK2 than CDK1, 2, 4, 5, and 7. |
M5228 | THZ1 | THZ1 is a covalent CDK7 inhibitor which has the unprecedented ability to target a remote cysteine residue located outside of the canonical kinase domain, providing an unanticipated means of achieving selectivity for CDK7. |
M1710 | Flavopiridol | Flavopiridol (Alvocidib) is a competitive broad-spectrum CDK inhibitor with IC50 of 30,170,100 nM against CDK1, CDK2 and CDK4, respectively. |
M6167 | Palbociclib | Palbociclib is a highly specific inhibitor of Cdk4 (IC50=11 nM) and Cdk6 (IC50=16 nM), having no activity against a panel of 36 additional protein kinases. |
M5305 | RO-3306 | RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with Ki of 20 nM, >15-fold selectivity against a diverse panel of human kinases. |
M4889 | Ribociclib succinate (LEE011 succinate) | Ribociclib succinate (LEE011 succinate) is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. |
M11247 | CAN508 | CAN508 was an effective AND ATP-competitive inhibitor of CDK9/cyclin T1 with IC50 of 0.35 μM. CAN508 is 38 times more selective for CDK9/cyclin T1 than other CDK/cyclin. CAN508 has antitumor activity. |
M11010 | Aminopurvalanol A | Aminopurvalanol A is a selective, cell-permeable, reversible and ATP-competitive cyclin-dependent kinase (CDK) inhibitor, inhibiting cdk1/cyclin B, cdk2/cyclin A, cdk2/cyclin E, and cdk5/p35. Aminopurvalanol A causes the inhibition of sperm fertilizing ability via the inhibition of physiological capacitation-dependent actin polymerization. |
M10966 | SY-5609 | SY-5609 (CDK7-IN-3) is an orally active, highly selective, noncovalent CDK7 inhibitor with a KD of 0.065 nM. SY-5609 shows poor inhibition on CDK2 (Ki=2600 nM), CDK9 (Ki=960 nM), CDK12 (Ki=870 nM). |
M10930 | Dalpiciclib | Dalpiciclib (SHR-6390) is a highly selective, oral bioavailable inhibitor of CDK4/6 that is used against CDK4 (IC50=12.4 nM) and CDK6 (IC50=9.9 nM) is equivalent. SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb protein and inducing G1 cell cycle blocking. |
M10871 | PF-07104091 | Pf-07104091 is an oral bioavailable, selective CDK2 inhibitor with a Ki value of 1.16 nM against CDK2/ Clin E1. Pf-07104091 has antitumor activity against cyclinE amplified cancers. |
M10843 | KB-0742 dihydrochloride | KB-0742 dihydrochloride is a potent, selective and orally active CDK9 inhibitor against CDK9/cyclin T1 IC50 is 6 nM. KB-0742 dihydrochloride is selective for CDK9/cyclin T1, which is more than 50 times more selective than other CDK kinases. KB-0742 dihydrochloride has potent anti-tumor activity. |
M10734 | YKL-5-124 | YKL-5-124 is a potent, selective, irreversible COVALENT inhibitor of CDK7 and CDK7/Mat1/CycH IC50 53.5 nM and 9.7 nM, respectively. YKL-5-124 is more than 100 times more selective to CDK7 than CDK9 and CDK2 and is inactive to CDK12 and CDK13. YKL-5-124 induces intense cell cycle arrest and inhibits E2F-driven gene expression with little effect on RNA polymerase II phosphorylation status. |
M10707 | FIT-039 | FIT-039 is a selective, ATP-competitive, orally active CDK9 inhibitor against CKD9/cyclin T1 IC50 Is 5.8 μM. FIT-039 does not inhibit other CDKs and other kinases. FIT-039 inhibits HSV-1 (IC50 is 0.69 μM), HSV-2, human adenovirus, and human CMV replication. FIT-039 is a promising antiviral agent that can be used to suppress resistant HSV and other DNA viruses. |
M10706 | AZD4573 | AZD4573 is a potent and highly selective CDK9 inhibitor (IC50 values less than 4 nM) can be used to study hematologic malignancies. |
M10705 | NVP-2 | NVP-2 is an effective and selective ATP competitive cyclin-dependent kinase 9 (CDK9) probe that inhibits CDK9/CycT activity.IC50 The value is 0.514 nM. NVP-2 has inhibitory effects on CDK1/CycB, CDK2/CycA and CDK16/CycY kinases, which IC50 The values are 0.584 μM, 0.706 μM, and 0.605 μM, respectively. NVP-2 induces apoptosis. |
M10347 | Abemaciclib (LY2835219) | Abemaciclib (LY2835219) is a best-in-class, selective and effective dual inhibitor of CDK4 and CDK6, which inhibits CDK4/CDK6 activity with IC50 of 2 nM and 10 nM respectively. |
M10327 | Zotiraciclib | Zotiraciclib (TG02, SB1317) is an orally bioavailable, brain penetrant multi-kinase inhibitor of CDK2, JAK2, and FLT3 with IC50 values of 13, 73, and 56 nM, respectively. |
M10258 | SR-4835 | SR-4835 is a highly selective, dual inhibitor of CDK12 with IC50 values of 99 nM, Kd of 98 nM and CDK13 with Kd of 4.9 nM, respectively. |
M10033 | Trilaciclib | Trilaciclib (G1T28) is a potent first-in-class reversible CDK4/6 inhibitor with IC50 of 1 nM and 4 nM for CDK4/cyclin D1 and CDK6/cyclin D3, respectively. |
M9910 | CDKI-73 | Cdki-73 (LS-007) is an orally active and highly effective CDK9 inhibitor with Ki values of 4 nM, 4 nM and 3 nM against CDK9, CDK1 and CDK2, respectively. Cdki-73 down-regulates phosphorylation of RNA polymerase II. Cdki-73 is also an inhibitor of Rab11. |
M9779 | THZ531 | THZ531 is a covalent CDK12 and CDK13 inhibitor with IC50 values of 158 nM and 69 nM, respectively. |
M9761 | AZD-5597 | AZD-5597 is potent CDK inhibitor with in vitro anti-proliferative effects against a range of cancer cell lines. |
M9755 | CYC065 | CYC065 (Fadraciclib) is an orally bioavailable inhibitor of cyclin dependent kinases 2 and 9 (CDK2/9) with IC50 values of 5 and 26 nM, respectively. |
M9622 | BAY-1143572 Racemate | BAY-1143572 Racemate (Atuveciclib Racemate) is the racemate mixture of Atuveciclib, Atuveciclib is a potent and highly selective, oral P-TEFb/CDK9 inhibitor which supresses CDK9/CycT1 with an IC50 of 13 nM. |
M9558 | JSH-150 | JSH-150 is a potent CDK9 inhibitor with IC50 of 1 nM. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.